Indian Journal of Rheumatology

ORIGINAL ARTICLE
Year
: 2021  |  Volume : 16  |  Issue : 1  |  Page : 49--56

Evaluation of oral rebamipide as a potential therapy for Sjögren syndrome-related dry eye and mouth


Vineet Mutha1, Yogita Gupta1, Noopur Gupta1, Murugesan Vanathi1, Seema Sen2, Uma Kumar3, Radhika Tandon1 
1 Dr Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India
2 Department of Ocular Pathology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India
3 Department of Medicine, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India

Correspondence Address:
Dr. Radhika Tandon
Room 490, 4th Floor, Dr Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, Ansari Nagar, New Delhi - 110 029
India

Background: Efficacy and safety of orally administered rebamipide was assessed in treating dry eye disease (DED) and xerostomia in Sjögren syndrome (SS) patients. Methods: Patients of SS with bilateral DED and xerostomia were offered a choice between either oral rebamipide (100 mg BID) with topical 0.5% carboxymethylcellulose (CMC) (R + CMC group) or CMC alone (CMC group), for 3 months, in a quasi-experimental study. Outcome measures were tear-film break-up time (TBUT) and xerostomia symptoms (XS), Schirmer's test (ST), Lissamine green staining grade (LGSG) and goblet cell density (GCD), Saxon salivary secretion test (SSST), and Ocular Surface Disease Index (OSDI). Results: Twenty patients were enrolled in each group. Those who preferred oral rebamipide had worse ST (P = 0.04), LGSG (P = 0.04), SSST (P = 0.006), and GCD (P = 0.009). At 1, 2, and 3 months, the mean increase in TBUT were, respectively, 3.4, 2.9, and 3.45 s in R + CMC, higher than CMC (P < 0.001). Improvement in ST was significantly higher in R + CMC (from 6.75 ± 0.43 to 12.6 ± 1.23 mm) than CMC (P < 0.001). The improvement in OSDI, LGSG, and XS was higher in R + CMC group (all P < 0.001), while that in SSTT (P = 0.6) and GCD (P = 0.7) was similar. No serious adverse events were seen. Conclusion: The dry eye and mouth showed improvement with oral rebamipide, proving its dual therapeutic action in SS.


How to cite this article:
Mutha V, Gupta Y, Gupta N, Vanathi M, Sen S, Kumar U, Tandon R. Evaluation of oral rebamipide as a potential therapy for Sjögren syndrome-related dry eye and mouth.Indian J Rheumatol 2021;16:49-56


How to cite this URL:
Mutha V, Gupta Y, Gupta N, Vanathi M, Sen S, Kumar U, Tandon R. Evaluation of oral rebamipide as a potential therapy for Sjögren syndrome-related dry eye and mouth. Indian J Rheumatol [serial online] 2021 [cited 2021 May 18 ];16:49-56
Available from: https://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2021;volume=16;issue=1;spage=49;epage=56;aulast=Mutha;type=0